The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for its first-in-class ivonescimab. Eli Lilly signed two more drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback